Peptide-Protocol.com
Key Benefits
Biologic Description
Developed in the late 1990s by Professor Frank Ng at Monash University, AOD 9604 is a revolutionary peptide, offering a modified version of human growth hormone (HGH). Its design uniquely aims to harness the fat-burning capabilities of HGH while avoiding any impact on blood sugar levels or growth abnormalities. This distinctive characteristic of AOD 9604 has garnered widespread attention from researchers worldwide.
As time progressed, the scope of AOD 9604's potential applications expanded beyond just weight loss. Researchers have delved into its possible roles in treating osteoarthritis and enhancing bone growth, showcasing the peptide's remarkable versatility.
The significance of AOD 9604 extends into various facets of modern medicine. In a world grappling with rising obesity rates, AOD 9604 offers a promising avenue for safe weight management as a fat-burning peptide and anti-obesity drug. Additionally, its potential in providing relief for the millions suffering from osteoarthritis and in boosting bone density for aging populations cannot be understated.
Continuing to pique the interest of the global scientific community, AOD 9604 presents exciting therapeutic possibilities. As we venture further into understanding this compound, new discoveries loom on the horizon.
Delving into the distinct properties of AOD 9604, it stands out among other peptides. Comprising 15 amino acids from the C-terminus end of Growth Hormone Polypeptide (GH), AOD 9604 is unique in its impact on insulin levels and its dual action in stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat accumulation). This sets it apart from other peptides that either focus on muscle growth or fat reduction.
In comparison with other common peptides like GHRP-6 and Ipamorelin, AOD 9604 uniquely does not impact insulin levels while actively promoting fat loss and preventing fat accumulation. Furthermore, studies indicate its safety for long-term use, highlighting its advantages over other peptides in terms of insulin impact, fat metabolism, and safety.
AOD 9604 is widely recognized for its weight loss benefits, owing to its manipulation of fat metabolism processes without affecting blood sugar levels or growth. Beyond this, it also contributes to muscle growth, making it appealing to bodybuilders and athletes, and has potential as a regenerative medicine product, aiding muscle recovery and cell regeneration.
The peptide also shows promise in areas still under research, such as bone strengthening, anti-inflammatory properties for conditions like arthritis, and improved skin elasticity through collagen production stimulation.
Understanding AOD 9604's mechanism of action provides further insight into its distinct qualities. Derived from the C-terminus end of Growth Hormone, it mimics the fat metabolism regulation of natural GH but without adverse effects on blood sugar or tissue growth. This differentiates it from other peptides and underlines its potential in weight management therapies. It not only stimulates lipolysis but also inhibits lipogenesis, offering a dual-action approach to fat management.
Furthermore, AOD 9604 enhances muscle recovery post-exercise, improves performance by boosting energy expenditure, and regulates muscle mass without affecting bone growth. These capabilities set it apart from most peptides used for similar purposes, marking it as a unique and promising compound in the field.
Dosage Guidelines
Navigating the complex world of peptides like AOD 9604 can be challenging, especially with limited FDA-approved peptide therapies. Understanding how to use these fat-burning peptides is crucial, but don't worry, we're here to help. It's important to know how to administer AOD 9604 safely, taking into account the recommended dosage and being aware of potential side effects.
The dosage of AOD 9604 varies based on your individual goals.
For weight loss, a common daily dosage ranges from 250mcg to 500mcg.
If your focus is on joint repair or seeking anti-aging benefits, you might need slightly higher doses, potentially up to 1000mcg.
Research indicates that it is safe for long-term use, but always remember to consult with a healthcare professional before starting any new supplement regimen, especially when dealing with potent compounds like AOD 9604.
250-500 mcg
Daily
4-8 Weeks
Side Effects
AOD 9604 stands out among weight loss supplements and injections due to its relatively low risk of side effects.
Typically, users might experience mild and temporary issues such as upset stomach, headaches, and discomfort at the injection site.
In rare cases, individuals might experience discomfort in their joints and there have been reports of heart palpitations in a few instances.
Unlike many other peptides, AOD 9604 does not affect insulin levels, adding to its safety profile.
Additionally, AOD 9604 could interact with other medications or supplements, so it's crucial to consult a healthcare professional before beginning any dosage cycle to ensure safe and effective use.
In none of the studies did a withdrawal or serious adverse event occur related to intake of AOD9604.
References:
Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health
AOD9604 was found to be generally safe after chronic oral application in rats and cynomolgus monkeys. There was no evidence of any genotoxic activities of AOD9604, as examined in an Ames test, a chromosomal aberration assay, or a bone micronucleus assay. Rat whole-body radiography revealed similar organ distribution after IV or oral application. Orally administered AOD9604 in pigs was well absorbed and results revealed rapid degradation kinetics.
Author: Margret I. Moréa, David Kenleyb
Publication Date: June 2014
Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans
AOD9604 had no effect on serum IGF-1 levels, which confirms the hypothesis that AOD9604 does not act via IGF-1. Results of oral glucose tolerance test demonstrated that, in contrast with hGH, AOD9604 has no negative effect on carbohydrate metabolism. There were no anti-AOD9604 antibodies detected in any of the patients selected for antibody assay. In none of the studies did a withdrawal or serious adverse event occur related to intake of AOD9604.
Authors: Heike Stiera, Evert Vosb, David Kenleyb
Published: April 2013
The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice andβ 3-AR Knock-Out Mice
Both human GH (hGH) and a lipolytic fragment (AOD9604) synthesized from its C-terminus are capable of inducing weight loss and increasing lipolytic sensitivity following long-term treatment in mice. One mechanism by which this may occur is through an interaction with theβ -adrenergic pathway, particularly with theβ 3-adrenergic receptors (β3-AR). Here we describe how hGH and AOD9604 can reduce body weight and body fat in obese mice following 14 d of chronic ip administration. These results correlate with increases in the level of expression ofβ 3-AR RNA, the major lipolytic receptor found in fat cells. Importantly, both hGH and AOD9604 are capable of increasing the repressed levels of β3-AR RNA in obese mice to levels comparable with those in lean mice. The importance ofβ 3-AR was verified when long-term treatment with hGH and AOD9604 in β3-AR knock-out mice failed to produce the change in body weight and increase in lipolysis that was observed in wild-type control mice. However, in an acute experiment, AOD9604 was capable of increasing energy expenditure and fat oxidation in theβ 3-AR knock-out mice. In conclusion, this study demonstrates that the lipolytic actions of both hGH and AOD9604 are not mediated directly through the β3-AR although both compounds increase β3-AR expression, which may subsequently contribute to enhanced lipolytic sensitivity.
Authors: Mark Heffernan, Roger J. Summers, Anne Thorburn, Esra Ogru, Robert Gianello, Woei-Jia Jiang, Frank M. Ng
Published: Dec 2001,
Central and Peripheral Molecular Targets for Anti-Obesity Pharmacotherapy
Obesity has emerged as one of the principle worldwide health concerns of the modern era, and there exists a tremendous unmet clinical need for safe and effective therapies to combat this global pandemic. The prevalence of obesity and its associated co-morbidities, including cardiovascular and metabolic diseases, has focused drug discovery and development on generating effective modalities for the treatment and prevention of obesity. Early efforts in the field of obesity pharmacotherapy centered on agents with indeterminate mechanisms of action producing treatment paradigms characterized by significant off-target effects. During the past two decades, new insights have been made into the physiologic regulation of energy balance and the subordinate central and peripheral circuits coordinating appetite, metabolism, and lipogenesis. These studies have revealed previously unrecognized molecular targets for controlling appetite and managing weight from which has emerged a new wave of targeted pharmacotherapies to prevent and control obesity.
Authors: Michael A. Valentino, Jieru E. Lin, and Scott A. Waldman
Published: 2011 Jul